Literature DB >> 16210674

Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab.

Antonio Salar, Beatriz Bellosillo, Sergio Serrano, Carlos Besses.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210674     DOI: 10.1200/JCO.2005.02.6138

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis.

Authors:  Concepción Fernández; Beatriz Bellosillo; Mariana Ferraro; Agustín Seoane; Blanca Sánchez-González; Silvia Pairet; Aina Pons; Luis Barranco; María Carmen Vela; Eva Gimeno; Lluís Colomo; Carles Besses; Alfons Navarro; Antonio Salar
Journal:  Cancer Genomics Proteomics       Date:  2017-01-02       Impact factor: 4.069

Review 2.  Therapy of gastric mucosa associated lymphoid tissue lymphoma.

Authors:  Andrea Morgner; Renate Schmelz; Christian Thiede; Manfred Stolte; Stephan Miehlke
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 3.  Recent Advances in the Genetic of MALT Lymphomas.

Authors:  Juan José Rodríguez-Sevilla; Antonio Salar
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

4.  Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome.

Authors:  Mar García; Beatriz Bellosillo; Blanca Sánchez-González; Francesc García-Payarols; Agustin Seoane; Ana Maria Ferrer; Eva Gimeno; Luis Eugenio Barranco; Ariadna Torner; Francesc Solé; Carles Besses; Sergi Serrano; Antonio Salar
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

Review 5.  Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma.

Authors:  Magdalena Witkowska; Piotr Smolewski
Journal:  Mediators Inflamm       Date:  2013-03-28       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.